**Shortage of Saxenda (liraglutide)
6 mg/ml solution for injection in pre-filled pens**

| **Indication** | Saxenda is a medicine used along with diet and increased physical activity to help manage weight in:  
• adults who have obesity (a body-mass index – BMI – of 30 or more);  
• adults who are overweight (have a BMI between 27 and 30) and have weight-related complications such as type 2 diabetes, abnormally high levels of fat in the blood, high blood pressure or obstructive sleep apnoea (frequent interruption of breathing during sleep);  
• adolescents from 12 years of age who have a BMI of 30 or more (obesity) and who weigh more than 60 kg. |
| **Reason for shortage** | There has been an increase in demand for Saxenda which has led to intermittent supply shortages which may continue until the end of 2024.  
The supply shortage is not related to a quality defect of the product or a safety issue. |
| **Member States affected** | Austria, Finland and Italy.  
This information may change. For up-to-date information about the status of a medicine shortage in a particular EU/EEA Member State, consult the national shortage register or contact the national competent authority. |
| **Monitoring of shortage** | EMA’s [SPOC working party](#) is closely monitoring the supply situation and engaging with the marketing authorisation holder and other stakeholders to identify measures to mitigate the impact of the supply shortage.  
The SPOC working party is responsible for monitoring and reporting events that could affect the supply of medicines in the EU. Summaries of the SPOC working party meetings can be found on [EMA’s website](#). |
| **Information for healthcare** | • An increase in demand for Saxenda has led to intermittent supply shortages that are expected to continue until the end of 2024. |

---

1 This document was modified on 6 February 2024 and 24 June 2024 to update information on the expected date of resolution.
2 The [SPOC working party](#) is responsible for monitoring and reporting events that could affect the supply of medicines in the EU. Summaries of the SPOC working party meetings can be found on [EMA’s website](#).
**Shortage of Saxenda (liraglutide)**

*6 mg/ml solution for injection in pre-filled pens*

| professionals | Healthcare professionals should ensure that patients at risk of running out of Saxenda are switched in time to a suitable alternative based on their clinical judgement. |
| - | For additional information consult your country’s national shortage register or contact your national competent authority. |

| Information for patients | An increase in demand for Saxenda has led to intermittent supply shortages that may last until the end of 2024. |
| - | If you are at risk of running out of Saxenda you should make an appointment with your healthcare professional to discuss switching to a suitable alternative. |
| - | If you have any questions, speak to your doctor or pharmacist. |
| - | For additional information consult your country’s national shortage register or contact your national competent authority. |

**Status**

Ongoing